Licorice Compound Helps Improve Lung Scarring by Blocking Specific Cell Signals

Jenn Hoskins
26th June, 2024

Licorice Compound Helps Improve Lung Scarring by Blocking Specific Cell Signals

Licorice plant (Glycyrrhiza glabra), source of 18β-GA.

Photo adapted from: Galyna Mykytynets / CC BY (Source)

Key Findings

  • Researchers from Anhui University of Science and Technology, China, found that 18β-Glycyrrhetinic acid (18β-GA) from licorice can help treat idiopathic pulmonary fibrosis (IPF)
  • In mouse models, 18β-GA significantly reduced lung inflammation, improved lung function, and decreased collagen buildup, slowing the progression of lung scarring
  • The study showed that 18β-GA blocks key proteins involved in lung cell changes that lead to fibrosis, offering a new potential treatment pathway for IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by the formation of scar tissue within the lungs, leading to severe respiratory issues and a poor prognosis. The cause of IPF is unknown, and treatment options are limited. Current therapies include pirfenidone and nintedanib, but their effectiveness varies, and many patients experience rapid disease progression[2][3]. To address the urgent need for more effective treatments, researchers from Anhui University of Science and Technology, China, investigated the potential of 18β-Glycyrrhetinic acid (18β-GA), a bioactive component in licorice, to alleviate IPF[1]. The study focused on the TGF-β1/JAK2/STAT3 signaling pathway, which is known to play a crucial role in the progression of IPF. Transforming growth factor-beta 1 (TGF-β1) is a protein that contributes to the development of fibrosis by promoting the transformation of normal lung cells into myofibroblasts, which produce excessive collagen, leading to tissue scarring. The JAK2/STAT3 pathway is involved in cell signaling and has been implicated in various inflammatory and fibrotic diseases. In their research, the team used a mouse model of bleomycin (BLM)-induced pulmonary fibrosis to evaluate the effects of 18β-GA. Bleomycin is a chemical that induces lung fibrosis, mimicking the pathological features of IPF. The in vivo experiments demonstrated that 18β-GA significantly reduced lung inflammation, improved lung function, and decreased collagen deposition, indicating a marked attenuation of pulmonary fibrosis progression. To further understand the mechanisms behind these effects, the researchers conducted in vitro experiments using lung alveolar epithelial cells and fibroblasts. They found that 18β-GA inhibited the activation and migration of fibroblasts induced by TGF-β1. Additionally, 18β-GA regulated the expression of key proteins involved in epithelial-mesenchymal transition (EMT)—a process where epithelial cells transform into mesenchymal cells, contributing to fibrosis. Specifically, 18β-GA modulated the levels of vimentin, N-cadherin, and E-cadherin proteins, thereby inhibiting TGF-β1-induced EMT. The study's findings highlight the potential of 18β-GA as a novel therapeutic agent for IPF by targeting the TGF-β1/JAK2/STAT3 signaling pathway. This pathway's involvement in IPF has been previously documented, and targeting it could provide a strategic approach to mitigating the disease's progression[2][3]. Moreover, the ability of 18β-GA to reduce inflammation and collagen deposition aligns with the need for treatments that address the underlying mechanisms of IPF rather than just alleviating symptoms[2]. Previous studies have emphasized the importance of early and accurate diagnosis of IPF, as well as the need for individualized therapeutic strategies[2][3]. The identification of biomarkers and the understanding of disease mechanisms are crucial for better disease stratification and treatment planning. The current study adds to this body of knowledge by elucidating the role of 18β-GA in modulating key signaling pathways involved in IPF, thus offering a potential new avenue for therapy. Additionally, environmental factors such as air pollution have been shown to exacerbate IPF, highlighting the complexity of the disease and the need for multifaceted treatment approaches[4]. The anti-inflammatory and antioxidant properties of 18β-GA could also offer protective benefits against environmental triggers, further supporting its therapeutic potential. The development of advanced in vitro models has been suggested as a means to improve pre-clinical drug testing and reduce reliance on animal models[5]. The findings from the Anhui University study could pave the way for further research using these models to explore the efficacy of 18β-GA and other potential treatments in a controlled environment, ultimately accelerating the discovery of effective therapies for IPF. In conclusion, the research conducted by Anhui University of Science and Technology demonstrates that 18β-Glycyrrhetinic acid holds promise as a novel treatment for idiopathic pulmonary fibrosis by targeting the TGF-β1/JAK2/STAT3 signaling pathway. This study contributes to the ongoing efforts to find more effective therapies for this debilitating disease, potentially improving outcomes for patients with IPF.

MedicineHealthBiochem

References

Main Study

1) 18β-Glycyrrhetinic Acid Ameliorates Bleomycin-induced Idiopathic Pulmonary Fibrosis via Inhibiting TGF-β1/JAK2/STAT3 Signaling Axis.

Published 23rd June, 2024

https://doi.org/10.1016/j.jsbmb.2024.106560

Related Studies

2) Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history.

https://doi.org/10.1111/resp.12683

3) Natural history of idiopathic pulmonary fibrosis.

https://doi.org/10.1016/j.rmed.2015.02.002

4) Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis.

https://doi.org/10.1136/thoraxjnl-2017-209967

5) Engineered cell and tissue models of pulmonary fibrosis.

https://doi.org/10.1016/j.addr.2017.12.013


Related Articles

An unhandled error has occurred. Reload 🗙